The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
So just watched the past company presentation .
I find I weird that after JM explained there is a Million quids plus worth of business in the pipeline and he would update the market obviously on new contracts but then said the company would also update the market if they we trading over expectations then said “say for example 10% over”
I find that very very bizarre. JM isn’t the guy to over promise and under deliver….
My gut feeling especially with the new recruitment is they know the contracts are all but done and it’s greater than the 10% above market expectations.
Why would anyone ever leave themselves exposed like that if they weren’t gonna deliver!!!!
PYC Sharing Merck Tweets today - ohhhhh the Irony.... haaaaaa.
News flow rich season - at this MC no Brainer if you ask me
Doesn't take a rocket scientist to see there is value down here.
As Laura rightly mentions there is news on numerous front as well as the 6 Mill potential from Val that's x3 the current MC
Also doesn't take a rocket scientist to look at the previous RNS feeds to understand historically December is a New heavy month...
Also hopefully just hopefully someone would have realised that the MERCK contracts run in cycles and normally renewed each December
Happy 1st December xxx
With the sheer size of this - I'm confident this will hit international business news - the current largest deposits are in China and Mozambique - EEE Dwarfs there deposits
Get what yours saying.....but to be honest anything at these prices are ridiculous - the whole prospect is HUGE.
Buy and wait....haven't seen anything on this scale ever.... certain we will all be rewarded.
In my view this will rise pretty quickly in the coming sessions when todays news/madness is absorbed i think after 12 is breached it runs from there into high teens. IMO
Good Luck All
I remember that Namibia drill - ridiculous mismanagement
Death Spiral - This Board are Awful
Rinsed people for decades
None of this he said / she said / it said makes no difference to the fundamentals on the company it’s peoples opinions - wrongly or rightly.
It’s in everyone’s best interest IMO to share relevant information or knowledge so people can make a subjective view on PYC.
Hearsay is nonsense
Maybe people should look at the MHRA guidelines on medical devices - rather interesting- especially the stages and guidelines and timelines for approval of PYC where to move this way????
Called it. Still many news fronts to come
I think todays performance was expect. However they’re clearly an appetite.
From a LTH I wouldn’t be surprised to see some other news pretty quickly - maybe even This week or next
Hi Taffy,
Sorry to hear that and I wish you all the best.
My understanding is that the dosing procedure in the chemotherapy is more or less a one size fits all process. Whereby someone get X Y Z sessions.
This movement in the sector towards precision dosing is that this method doesn’t take individuality into account therefore valuable time is used, people are either under dosed or over dosed which ultimately has massive effects either side of the scale.
The precision dosing application is designed to be specific to an individual therefore allowing Dr’s etc to determine the correct dosing to enhance efficiency to that individual.
All the best
KH
Join the dots maybe…Update due on this separate collaboration maybe!!!
Tabula Rasa HealthCare® (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, announces today it has entered into a partnership with Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalized medicine solutions. Through this initiative, Physiomics’ personalized docetaxel model will be integrated into TRHC’s market-leading precision dosing solution, DoseMeRx®. Both parties expect positive feedback from this initial trial with the next step being a commercial agreement.
Cancer remains one of the leading causes of death in developed countries and one of the most significant areas of spend for health systems. There are many effective cancer drugs; but, it is well established that, given the same dose, variations between individuals mean that different amounts of drug reach their tumours.
Using measurements of the amount of drug in a patient’s blood to guide what dose they should receive has been shown to improve efficacy and reduce side effects. The tests, however, are difficult to obtain in oncology since they are expensive and not standardized. Physiomics’ personalized dosing models currently rely only on inexpensive, standard blood tests that could help doctors and pharmacists in making decisions about the dose of cancer drugs for individual patients. TRHC’s DoseMeRx enables healthcare providers to optimize dosing and streamline operations, reduce adverse drug events, and decrease costs. The unique DoseMeRx platform incorporates Bayesian science to guide the safe and effective dosing of 42 different drugs.
Physiomics Chief Executive Officer, Jim Millen, MD, said, “Initially, we will focus on the drug docetaxel, which is commonly used to treat prostate, breast and other cancers. However, one of our goals is to establish how this could potentially be extended to apply to other drugs and cancer types. We partnered with TRHC because its DoseMeRx solution has been the leader in the personalized dosing field for several years, and they have demonstrated the ability to not only lead the science, but to make it accessible for those who can benefit from it. We look forward to the results of the trial and potentially entering into a revenue generating contract in due course.”
TRHC Chief Scientific Officer Jacques Turgeon, BPharm, PhD, added, “The focus of the collaboration is on delivering better outcomes for cancer patients. Incorporating this new science into DoseMeRx will enable clinicians to more effectively predict the timing of serious adverse effects, such as neutropenia, that are commonly observed in patients receiving chemotherapy. We have seen a great deal of success in infectious diseases through the use of DoseMeRx, and we are excited to expand this into oncology.”
Baserite - i would agree
PYC tech is already integrated into DosemeRX a Tabula Rasa Healthcare assest
DosemeRX is already used globally in 10,000 medical outfits (Portuguese healthcare system for example) USA and Australia
Tabula Ras Health Care MC £130 Million
DosemeRX is integrated into
Ilun Health Tech (Merck) MC £207 Billion
Also integrated into
Wolters Kluwer Healthcare Tech (MC £27 Billion)
This could get very very big very quickly
2017 was a spike based on a 500k Merck Contract i seem to remember
Todays RNS a result from the Trial on the Dosing Application that has been worked on by PYC for many years.
These Results indicate a pathway to commercialisation for a medical device that can be used globally.
The significance of this RNS and pathway forward are incredible
Lost in Space - you havent seen the last investors presentation then i guess?
Enough Cash for 2 years
Thanks
KH
Docetaxel (CHEMO DRUG) used in PYC Dosing Application global sales $3.1 Billion
This Tech can be used globally as a medical device - NHS will be all over this.
FDA Fast Track Project Optimus
Multiples and multiples of current MC
News due Q1 as stated above
This is random RNS or movement - PYC have been working on this tech for years and its coming to commercialisation points
Huge milestone - momentum will build fast on this now imo
Twice lol
Not many shares in issue - moves rapid on proper volume
Agreed.
Most days lol without NT even with F A Trades haa